Definium Therapeutics, Inc. Asset Resilience Ratio
Definium Therapeutics, Inc. asset resilience ratio. Definium Therapeutics, Inc. (DFTX) has an Asset Resilience Ratio of 38.51% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Definium Therapeutics, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Definium Therapeutics, Inc. (2017–2025)
Asset resilience ratio of Definium Therapeutics, Inc. from 2017 to 2025. This chart shows how Definium Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read DFTX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Definium Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DFTX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $428.61 Million | 38.51% |
| Total Liquid Assets | $428.61 Million | 38.51% |
Asset Resilience Insights
- Very High Liquidity: Definium Therapeutics, Inc. maintains exceptional liquid asset reserves at 38.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Definium Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Definium Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Definium Therapeutics, Inc. Asset Resilience Ratio by Year (2017–2025)
Definium Therapeutics, Inc. asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Definium Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.94% | $153.76 Million | $440.10 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $302.15 Million | -- |
| 2017-12-31 | 41.88% | $1.69 Million | $4.03 Million | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more